# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrol...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Buy and maintains ...
Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with co...
Wells Fargo analyst Eva Fortea Verdejo initiates coverage on ITeos Therapeutics (NASDAQ:ITOS) with a Overweight rating and a...